Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

A small molecule–kinase interaction map for clinical kinase inhibitors

2005 • 1,854 citations

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

2004 • 1,785 citations

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

2006 • 1,734 citations

Chronic Myeloid Leukemia

1999 • 1,639 citations

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

2005 • 1,435 citations

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 • 1,349 citations

Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

2004 • 1,249 citations

Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

2005 • 1,007 citations

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

2002 • 925 citations

Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

2003 • 843 citations

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571

2002 • 675 citations

ILK, PINCH and parvin: the tIPP of integrin signalling

2005 • 650 citations

The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants

2006 • 645 citations

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

2005 • 556 citations

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

2006 • 458 citations

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

2004 • 404 citations

Imatinib as a Paradigm of Targeted Therapies

2004 • 366 citations

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors

2003 • 332 citations

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

2007 • 277 citations

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors

2000 • 232 citations

Crystal Structure of Quinone Reductase 2 in Complex with Resveratrol^,

2004 • 230 citations

Profiling Core Proteomes of Human Cell Lines by One-dimensional PAGE and Liquid Chromatography-Tandem Mass Spectrometry

2003 • 230 citations

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

2003 • 226 citations

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

2003 • 219 citations

Overexpression of the Cell Adhesion Molecules DDR1, Claudin 3, and Ep-CAM in Metaplastic Ovarian Epithelium and Ovarian Cancer

2004 • 207 citations

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling

2005 • 201 citations

Rescuing drug discovery: in vivo systems pathology and systems pharmacology

2005 • 200 citations

A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain.

1993 • 177 citations

NRH:quinone reductase 2: An enzyme of surprises and mysteries

2005 • 146 citations

Discoidin Domain Receptor-1a (DDR1a) Promotes Glioma Cell Invasion and Adhesion in Association with Matrix Metalloproteinase-2

2005 • 115 citations

Identification and Characterization of a Novel MAP Kinase Kinase Kinase, MLTK

2001 • 113 citations

Crystal Structure of Human Quinone Reductase Type 2, a Metalloflavoprotein^,

1999 • 101 citations

Activation of Discoidin Domain Receptor 1 Isoform b with Collagen Up-Regulates Chemokine Production in Human Macrophages: Role of p38 Mitogen-Activated Protein Kinase and NF-κB

2004 • 97 citations

Regulating the regulator: negative regulation of Cbl ubiquitin ligases

2006 • 94 citations

Lindvall, J. M. et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 203, 200-215

2005 • 56 citations

Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography

2007 • 55 citations

Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.

1987 • 55 citations

The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib Therapy

2007 • 50 citations

Case histories, magic bullets and the state of drug discovery

2006 • 47 citations

Characterisation of kinase-selective inhibitors by chemical proteomics

2005 • 44 citations

Discoidin Domain Receptor 1: A New Class of Receptor Regulating Leukocyte-Collagen Interaction

2005 • 43 citations

The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.

2006 • 42 citations

Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium

2001 • 27 citations

Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor

2006 • 25 citations

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy.

2006 • 22 citations

Involvement of Discoidin Domain Receptor 1 in the Deterioration of Pulmonary Sarcoidosis

2005 • 20 citations

Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI).

2006 • 12 citations